Trials / Conditions / Neurotransmitter Agents

Neurotransmitter Agents

11 registered clinical trials studyying Neurotransmitter Agents — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU) NCT07210463	Merz Aesthetics GmbH	Phase 3
Recruiting	A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States NCT07122193	Merz North America, Inc.	Phase 3
Not Yet Recruiting	Efficacy of Satisens® in Reducing Emotional Eating NCT07079046	José Enrique de la Rubia Ortí, Ph	N/A
Recruiting	Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Trea NCT06511908	National Institute of Mental Health (NIMH)	Phase 2
Recruiting	Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting NCT06752759	Theresa Jacob, PhD, MPH	Phase 3
Recruiting	Natural History of Depression, Bipolar Disorder and Suicide Risk NCT06462196	National Institute of Mental Health (NIMH)	—
Completed	Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression NCT05615948	Maimonides Medical Center	Phase 4
Completed	Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder NCT05321602	Luye Pharma Group Ltd.	Phase 1
Completed	Relative Bioavailability of LY03010 Compared to Listed Drug NCT04922593	Luye Pharma Group Ltd.	Phase 1
Completed	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader NCT05657860	Maimonides Medical Center	Phase 4
Unknown	Lidocaine and Magnesium and Ketamine in Gynecological Surgery NCT04622904	Aretaieion University Hospital	N/A